Literature DB >> 2021854

Improving results in the treatment of gastric cancer: an 11-year audit.

J A Akoh1, D M Sedgwick, I M Macintyre.   

Abstract

Of 280 patients presenting to one hospital with gastric cancer between 1975 and 1985, 97 (35 per cent) did not undergo surgery and 29 per cent (54 out of 183) of those who did had no resection performed. The 30-day operative mortality rate in the study period was 15 per cent (28 out of 183) but in the subsequent 4-year period this fell to 7 per cent (5 out of 69). The survival rate correlated significantly with depth of invasion but not with tumour site or degree of differentiation. The incidence of early gastric cancer in this series was 5 per cent but the 5-year survival rate in this group was 52 per cent suggesting that the true incidence might be even lower. The overall 5-year survival rate in our area 20 years ago was only 5.2 per cent but in this series it was 11 per cent overall and 24 per cent after resection, and with actuarial correction 15 per cent overall and 28 per cent after resection. The continuing improvement in operative mortality rates and in 5-year survival rates gives grounds for optimism, but the disease must be diagnosed earlier if this improvement in outlook is to continue.

Entities:  

Mesh:

Year:  1991        PMID: 2021854     DOI: 10.1002/bjs.1800780325

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  9 in total

1.  Unchanging workload in gastric cancer.

Authors:  D M Sedgwick; I M Macintyre
Journal:  BMJ       Date:  1991-08-24

2.  Gastric cancer in Scotland: changing epidemiology, unchanging workload.

Authors:  D M Sedgwick; J A Akoh; I M Macintyre
Journal:  BMJ       Date:  1991-06-01

3.  Gastric cancer: a curable disease in Britain.

Authors:  H M Sue-Ling; D Johnston; I G Martin; M F Dixon; M R Lansdown; M J McMahon; A T Axon
Journal:  BMJ       Date:  1993-09-04

4.  Effect of histamine on the growth of human gastrointestinal tumours: reversal by cimetidine.

Authors:  S A Watson; L J Wilkinson; J F Robertson; J D Hardcastle
Journal:  Gut       Date:  1993-08       Impact factor: 23.059

5.  Preservation of the spleen improves survival after radical surgery for gastric cancer.

Authors:  J P Griffith; H M Sue-Ling; I Martin; M F Dixon; M J McMahon; A T Axon; D Johnston
Journal:  Gut       Date:  1995-05       Impact factor: 23.059

6.  Early gastric cancer: 46 cases treated in one surgical department.

Authors:  H M Sue-Ling; I Martin; J Griffith; D C Ward; P Quirke; M F Dixon; A T Axon; M J McMahon; D Johnston
Journal:  Gut       Date:  1992-10       Impact factor: 23.059

7.  Expression of oncoproteins and the amount of eosinophilic and lymphocytic infiltrates can be used as prognostic factors in gastric cancer. Dutch Gastric Cancer Group (DGCG).

Authors:  I Songun; C J van de Velde; J Hermans; S T Pals; H W Verspaget; A N Vis; A G Menon; S V Litvinov; J H van Krieken
Journal:  Br J Cancer       Date:  1996-12       Impact factor: 7.640

8.  Loss of Ep-CAM (CO17-1A) expression predicts survival in patients with gastric cancer.

Authors:  I Songun; S V Litvinov; C J H van de Velde; S T Pals; J Hermans; J H J M van Krieken
Journal:  Br J Cancer       Date:  2005-05-09       Impact factor: 7.640

9.  Pathological prognostic factors in the second British Stomach Cancer Group trial of adjuvant therapy in resectable gastric cancer.

Authors:  C C Yu; D A Levison; J A Dunn; L C Ward; M Demonakou; W H Allum; M T Hallisey
Journal:  Br J Cancer       Date:  1995-05       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.